DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Fischl MA, Stanley K, Collier AC, et al. Combination and monotherapy
with zidovudine and zalcitabine in patients with
advanced HIV disease. The NIAID AIDS Clinical Trials
Group. Ann Intern Med, 1995, 122:24–32.
Fitzsimmons ME, Collins JM. Selective biotransformation of the
human immunodeficiency virus protease inhibitor saquinavir
by human small-intestinal cytochrome P4503A4: Potential
contribution to high first-pass metabolism. Drug Metab
Dispos, 1997, 25:256–266.
Flexner C. HIV-protease inhibitors. N Engl J Med, 1998, 338:
1281–1292.
Flexner C. Dual protease inhibitor therapy in HIV-infected
patients: Pharmacologic rationale and clinical benefits. Annu
Rev Pharmacol Toxicol, 2000, 40:649–674.
Flexner C. HIV drug development: The next 25 years. Nature
Rev Drug Disc, 2007, 6:959–966.
Flexner C, Bate G, Kirkpatrick P. Tipranavir. Nature Rev Drug
Disc, 2005, 4:955–956.
Flexner C, Pham P. Drug-drug interactions in HIV-infected patients:
An interactive decision support tool. Clinical Care Options, LLC,
Washington, DC. First published August 14, 2006; last updated
May 30, 2009. Available at http://clinicaloptions.com/HIV/
Treatment%20Updates/Drug-Drug.
Foster C, Lyall H, Olmscheid B, et al. Tenofovir disoproxil
fumarate in pregnancy and prevention of mother-to-child
transmission of HIV-1: Is it time to move on from zidovudine?
HIV Med, 2009, 10:397–406.
Frank I, Bosch RJ, Fiscus S, et al., for the ACTG 307 Protocol
Team. Activity, safety, and immunologic effects of hydroxyurea
added to didanosine in antiretroviral naïve and experienced
HIV-1 infected subjects: A randomized, placebo-controlled
trial, ACTG 307. AIDS Res Hum Retroviruses, 2004,
20:916–926.
Fulco PP, McNicholl IR. Etravirine and rilpivirine: Nonnucleoside
reverse transcriptase inhibitors with activity against human
immunodeficiency virus type 1 strains resistant to previous nonnucleoside
agents. Pharmacotherapy, 2009, 29:281–294.
Gallant JE, Gerondelis PZ, Wainberg MA, et al. Nucleoside and
nucleotide analogue reverse transcriptase inhibitors: A clinical
review of antiretroviral resistance. Antivir Ther, 2003,
8:489–506.
Gallant JE, Moore RD. Renal function with use of a tenofovircontaining
initial antiretroviral regimen. AIDS, 2009, 23:
1971–1975.
Gallant JE, Staszewski S, Pozniak AL, et al., for the 903 Study
Group. Efficacy and safety of tenofovir DF vs stavudine in
combination therapy in antiretroviral-naive patients: A 3-year
randomized trial. JAMA, 2004, 292:191–201.
Gao WY, Agbaria R, Driscoll JS, Mitsuya H. Divergent antihuman
immunodeficiency virus activity and anabolic phosphorylation
of 2′,3′-dideoxynucleoside analogs in resting and
activated human cells. J Biol Chem, 1994, 269:12633–12638.
Gardner EM, Burman WJ, Steiner JF, et al. Antiretroviral medication
adherence and the development of class-specific antiretroviral
resistance. AIDS, 2009, 23:1035–1046.
Garg A. Acquired and inherited lipodystrophies. N Engl J Med,
2004, 350:1220–1234.
Geleziunas R, Arts EJ, Boulerice F, et al. Effect of 3′-azido-
3′-deoxythymidine on human immunodeficiency virus type 1
replication in human fetal brain macrophages. Antimicrob
Agents Chemother, 1993, 37:1305–1312.
Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV
testing with immediate antiretroviral therapy as a strategy for
elimination of HIV transmission: a mathematical model.
Lancet, 2009, 373:48–57.
Greene WC, Peterlin BM. Charting HIV’s remarkable voyage
through the cell: Basic science as a passport to future therapy.
Nature Med, 2002, 8:673–680.
Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir,
zidovudine and lamivudine in adults with human
immunodeficiency virus infection and prior antiretroviral therapy.
N Eng Med, 1997, 337:734–739.
Gulick RM Ribaudo HJ, Shikuma CM et al. Triple nucleoside regimens
versus efavirenz-containing regimens for the initial treatment
of HIV-1 infection. N Eng J Med, 2004, 350:1850–1861.
Haas DW, Gebretsadik T, Mayo G, et al. Associations between
CYP2B6 polymorphisms and pharmacokinetics after a single
dose of nevirapine or efavirenz in African Americans. J Infect
Dis, 2009, 199:872–880.
Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing
nucleoside monotherapy with combination therapy in
HIV-infected adults with CD4 cell counts from 200 to 500 per
cubic millimeter. AIDS Clinical Trials Group Study 175 Study
Team. N Engl J Med, 1996, 335:1081–1090.
Hammer SM, Squires KE, Hughes MD, et al. A controlled trial
of two nucleoside analogues plus indinavir in persons with
human immunodeficiency virus infection and CD4 cells
counts of 200 per cubic millimeter or less. N Eng J Med, 1997,
337: 725–733.
Harris M, Montaner JS. Clinical uses of non-nucleoside reverse
transcriptase inhibitors. Rev Med Virol, 2000, 10:217–229.
Havlir DV, Gilbert PB, Bennett K, et al., for the ACTG 5025
Study Group. Effects of treatment intensification with hydroxyurea
in HIV-infected patients with virologic suppression.
AIDS, 2001, 15:1379–1388.
Havlir D, McLaughlin MM, Richman DD. A pilot study to evaluate
the development of resistance to nevirapine in asymptomatic
human immunodeficiency virus-infected patients with
CD4 cell counts of >500/mm 3 : AIDS Clinical Trials Group
Protocol 208. J Infect Dis, 1995, 172:1379–1383.
Havlir DV, Tierney C, Friedland GH, et al. In vivo antagonism
with zidovudine plus stavudine combination therapy. J Infect
Dis, 2000, 182:321–325.
Hervey PS, Perry CM. Abacavir: A review of its clinical potential
in patients with HIV infection. Drugs, 2000, 60:447–479.
Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations
in HLA-B region and hypersensitivity reactions to abacavir.
Lancet, 2002, 359:1121–1122.
Hicks C, Gulick RM. Raltegravir: The first HIV type 1 integrase
inhibitor. Clin Infect Dis, 2009, 48:931–939.
Hirsch MS, D’Aquila RT. Therapy for human immunodeficiency
virus infection. N Engl J Med, 1993, 328:1686–1695.
HIV Neuromuscular Syndrome Study Group. HIV-associated neuromuscular
weakness syndrome. AIDS, 2004, 18:1403–1412.
Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of
plasma virions and CD4 lymphocytes in HIV-1 infection.
Nature, 1995, 373:123–126.
Hsu A, Granneman GR, Bertz RJ. Ritonavir: Clinical pharmacokinetics
and interactions with other anti-HIV agents. Clin
Pharmacokinet, 1998, 35:275–291.
Hurst M, Noble S. Stavudine: An update of its use in the treatment
of HIV infection. Drugs, 1999, 58:919–949.
1661
CHAPTER 59
ANTIRETROVIRAL AGENTS AND TREATMENT OF HIV INFECTION